US Patent

US10071985 — Therapeutic compounds

Composition of Matter · Assigned to Gilead Sciences Inc · Expires 2037-08-17 · 11y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds of formulas (Ia), (Ib), (IIa), and (IIb) for treating Retroviridae viral infections, including HIV.

USPTO Abstract

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: US10071985
Jurisdiction: US
Classification: Composition of Matter
Expires: 2037-08-17
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.